Anzeige
Mehr »
Login
Samstag, 19.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Trumps Dekret beschleunigt Antimon-Boom - Wird Global Tactical der nächste Highflyer für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AJ68 | ISIN: NL0011832936 | Ticker-Symbol: C43
Xetra
17.04.25
17:35 Uhr
51,50 Euro
-1,00
-1,90 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
COSMO PHARMACEUTICALS NV Chart 1 Jahr
5-Tage-Chart
COSMO PHARMACEUTICALS NV 5-Tage-Chart
RealtimeGeldBriefZeit
50,5051,5017.04.
50,00052,0017.04.

Aktuelle News zur COSMO PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.04.Romanian dietary supplement producer Cosmo Pharm opens EUR 2 million research and production lab4
COSMO PHARMACEUTICALS Aktie jetzt für 0€ handeln
01.04.Cosmo Pharmaceuticals ernennt neuen Chief Legal Counsel1
01.04.Cosmo Pharmaceuticals N.V.: Cosmo Appoints Federico Sommariva as Chief Legal Counsel327Dublin, Ireland--(Newsfile Corp. - April 1, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced the appointment of Federico Sommariva ad Chief Legal Counsel. Federico...
► Artikel lesen
21.03.Cosmo Pharmaceuticals reports FY results8
21.03.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals publishes Annual Report 2024402Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") has published today its Annual Report...
► Artikel lesen
06.03.Cosmo Pharmaceuticals N.V. reports FY results12
06.03.Cosmo wächst dank Schlüsselprodukten 2024 weiter324Dublin - Das Spezialitätenpharma-Unternehmen Cosmo hat 2024 einen Gewinnsprung verzeichnet. Der Umsatz hat sich derweil nahezu verdreifacht, wie das Unternehmen bereits Anfang Januar gemeldet hatte....
► Artikel lesen
06.03.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 202460Ad hoc announcement pursuant to Art. 53 LR FY 2024 Revenue of €266.8 million (unaudited) reaching upper end of guidance FY 2024 Operating Profit (unaudited) of €148.9 million...
► Artikel lesen
12.02.Cosmo Pharmaceuticals N.V.: Cosmo to Host Investor Day on April 9, 2025520Dublin, Ireland--(Newsfile Corp. - February 12, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") is pleased to announce that it will host an Investor Day on Wednesday, April 9...
► Artikel lesen
11.02.Cosmo Pharmaceuticals N.V.: Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio432Dublin, Ireland--(Newsfile Corp. - February 11, 2025) - Planet Friendly Technologies, Inc.Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced the appointment of Andrea Cherubini...
► Artikel lesen
10.02.Glenmark, Cosmo get MHRA nod for acne treatment medication3
10.02.Cosmo, Glenmark secure UK MHRA approval of Winlevi for treatment of acne4
10.02.Cosmo Pharmaceuticals N.V.: Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne365Dublin, Ireland and Mumbai, India and London, United Kingdom--(Newsfile Corp. - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") and Glenmark Pharmaceuticals Limited...
► Artikel lesen
28.01.Cosmo Pharmaceuticals N.V.: Invitation to Cosmo's Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025307Dublin, Ireland--(Newsfile Corp. - January 28, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN: C43) ("Cosmo") announced today that it will publish its unaudited Full-Year 2024 results on Thursday...
► Artikel lesen
09.01.Cosmo Pharmaceuticals estimates 186% Y/Y growth in 2024 revenue10
09.01.Cosmo weist für 2024 Umsatz von 265,7 Millionen Euro aus385Dublin - Das Biopharmaunternehmen Cosmo Pharmaceuticals hat gemäss ersten ungeprüften Angaben den Umsatz im Geschäftsjahr 2024 mit 265,7 Millionen Euro fast verdreifacht. Darin enthalten ist eine Art...
► Artikel lesen
09.01.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates696Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7 million (unaudited), marking a 186% increase compared to 2023. Financial Strength:...
► Artikel lesen
12.12.24Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Appoints Chief Strategy Officer431Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy...
► Artikel lesen
18.10.24Cosmo Pharmaceuticals N.V.: Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM467Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") shareholders today approved the proposal by the Board of Directors to appoint Deloitte...
► Artikel lesen
11.10.24Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Appoints New Chief Financial Officer483Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") is delighted to announce the appointment...
► Artikel lesen
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1